YOU SEARCHED BY...

Remove all

Contract Service Directory


FLAMMA





Company Headquarters

Via Bedeschi 22
Chignolo d'Isola (BG), 24040
Italia

Company Description

FLAMMA is a family owned & run CDMO, started in 1950, that specializes in the cGMP manufacture of APIs, NCEs, RSMs, & more. FLAMMA has 4 cGMP manufacturing facilities totaling 450 m3 of capacity – Italy (2), China & USA. FLAMMA provides a stable, reliable & integrated supply chain. A consistent industry award winner, FLAMMA is the THINKING CDMO.

Contract Service Directory

    Related Content

    • APIs | Breaking News | cGMP Manufacture | Industry News
      Flamma, Gilead Continue Mfg. Partnership for Veklury

      Flamma, Gilead Continue Mfg. Partnership for Veklury

      Flamma will continue to use its sites in Italy and China to support Gilead's network of manufacturers contributing to supply of Veklury.
      Contract Pharma Staff 11.06.20
    • Breaking News | Facilities | Industry News
      PCI Pharma Services Invests in Tredegar, UK Site

      PCI Pharma Services Invests in Tredegar, UK Site

      Doubles capacity to expand development and manufacturing capabilities.
      12.11.19
    • Analytical Services | Breaking News | Industry News | Vials
      Stevanato Group Begins Construction on TEC

      Stevanato Group Begins Construction on TEC

      New facility supports company’s U.S.-centric biopharma drug development operations
      12.05.19
    • APIs | Breaking News | Industry News
      Indena Focuses on Pharma

      Indena Focuses on Pharma

      Sells cosmetics biz to focus on core markets.
      11.27.19
    • Industrial Equipment Auctions and Liquidations

      Industrial Equipment Auctions and Liquidations

      ...
    • Five Steps to Ensure Your Cell and Gene Therapy Product Is GMP Compliant

      Five Steps to Ensure Your Cell and Gene Therapy Product Is GMP Compliant

      When we think about CGTs what most often comes to mind is the early stage scientific innovation responsible for finding new ways to treat diseases.
    • APIs | Cytotoxics and High Potency Manufacturing | Facilities
      Flamma Arrives in the U.S.

      Flamma Arrives in the U.S.

      Italian CDMO sets down roots in the U.S. market with purchase of Teva facility.
      Tim Wright, Editor, Contract Pharma 10.15.19

    • Contracting And Outsourcing Exhibitor List

      ...
      09.17.19
    • Cytotoxics and High Potency Manufacturing
      Highly Potent Expansions

      Highly Potent Expansions

      CDMOs see HPAPI demand rising
      S. Harachand, Contributing Editor 09.16.19
    • Cytotoxics and High Potency Manufacturing
      High Containment & Cost Savings with Single Use Isolator Technology

      High Containment & Cost Savings with Single Use Isolator Technology

      The trend towards HPAPIs is driving the need for innovative containment systems.
      Scott Patterson, Vice President Commercial Sales, ILC Dover 09.16.19
    • Cytotoxics and High Potency Manufacturing
      Handling & Assessing HPAPIs

      Handling & Assessing HPAPIs

      As oncology pipelines grow, so too is the demand for highly potent materials, which require careful handling and containment.
      Jason Korbel, Technical Services Manager, Cambrex Charles City 09.16.19
    • Cytotoxics and High Potency Manufacturing
      API to ADC: A Journey Through High Potency

      API to ADC: A Journey Through High Potency

      This class of compounds represents a major advance in oncology research and treatment application.
      Maurits Janssen, Head Commercial Development API, Lonza Pharma & Biotech 09.16.19
    • Bio News | Breaking News | Industry News | Validation
      Viralgen Receives EMA cGMP Certification

      Viralgen Receives EMA cGMP Certification

      Confirms commitment to flexible and robust AAV manufacturing capability
      09.05.19
    • Breaking News | Collaborations & Alliances | Excipients | Industry News
      Sterling Starts Large-scale Production of Nanologica’s Silica Particles

      Sterling Starts Large-scale Production of Nanologica’s Silica Particles

      First commercial batch is expected to be delivered during 2021
      08.28.19
    • Bio News | Breaking News | Industry News | Promotions & Moves | QA/QC | Regulatory Affairs
      Goodwin Biotechnology Bolsters Quality & Regulatory Capabilities

      Goodwin Biotechnology Bolsters Quality & Regulatory Capabilities

      Names Gerald Orehostky as vice president of quality and regulatory operations
      08.07.19
    • APIs | Breaking News | Facilities | Industry News
      FLAMMA Acquires Teva’s Philadelphia cGMP Facility

      FLAMMA Acquires Teva’s Philadelphia cGMP Facility

      Marks entry into the U.S. marketplace with labs & pilot plant
      07.01.19
    • Breaking News | Facilities | Industry News | Inspections
      Flamma Completes Successful CFDA Inspection

      Flamma Completes Successful CFDA Inspection

      Milestone is part of the Flamma 2020 Plan to bring improvement across the CDMO’s network of manufacturing sites
      03.21.19
    • APIs | Breaking News | Industry News
      Flamma Opens New cGMP Kilo Lab in Italy

      Flamma Opens New cGMP Kilo Lab in Italy

      Plans construction of new R&D building to quadruple space
      03.20.19
    • APIs | Breaking News | cGMP Manufacture | Facilities | Industry News
      Flamma Launches New cGMP Workshop

      Flamma Launches New cGMP Workshop

      The $20M Dalian, China facility is also an R&D center